[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 44 of about 44
1. Song X, Song Z, Lv Y, Zhong M, Li X: [The Study on Gene Amplification of EGFR in Bronchioloalveolar Carcinoma and Conventional Adenocarcinoma of the Lung.]. Zhongguo Fei Ai Za Zhi; 2009 Aug 20;12(8):879-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The Study on Gene Amplification of EGFR in Bronchioloalveolar Carcinoma and Conventional Adenocarcinoma of the Lung.].
  • BACKGROUND: Patients with adenocarcinoma of the lung have disproportionately response to the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
  • The aim of this study is to analyze the difference of EGFR gene amplification in bronchioloalveolar carcinoma (BAC), adenocarcinma mixed subtype and conventional adenocarcinoma of the lung and provide some information to clinical therapies.
  • METHODS: Lung cancer cases were collected and reviewed from the archives of the Department of Pathology, Chinese PLA General Hospital during the time period from 2004 to 2006.
  • The definite diagnosis of BAC based on 2004 WHO classification of lung tumors was made by two pathologists.
  • Fluorescence in situ hybridization (FISH) was performed to detect EGFR gene amplification in pure BAC, adenocarcinma mixed subtype and conventional adenocarcinoma.
  • RESULTS: Conventional adenocarcinoma had higher EGFR amplification compared with pure BAC and adenocarcinma mixed subtype (Chi-square=11.632, P<0.05).
  • EGFR gene amplification was found in 45.45% of conventional adenocarcinoma, 14.81% in pure BACs, and 22.58% in adenocarcinma mixed subtype.
  • EGFR gene amplification might be associated with the development of adenocarcinoma of the lung.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20719175.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Hatzibougias D, Bobos M, Karayannopoulou G, Karkavelas G, Karapanagiotidis GT, Foroulis CN, Kostopoulos I: A rare tumoral combination, synchronous lung adenocarcinoma and mantle cell lymphoma of the pleura. World J Surg Oncol; 2008;6:137
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare tumoral combination, synchronous lung adenocarcinoma and mantle cell lymphoma of the pleura.
  • BACKGROUND: Coexistence of adenocarcinoma and mantle cell lymphoma in the same or different anatomical sites is extremely rare.
  • We present a case of incidental discovery of primary lung adenocarcinoma and mantle cell lymphoma involving the pleura, during an axillary thoracotomy performed for a benign condition.
  • A bulla of the lung apex was resected en bloc with a scar-like lesion of the lung, which was located in proximity with the bulla origin, by a wide wedge resection.
  • Histologic examination of the stripped-off parietal pleura and of the bullectomy specimen revealed the synchronous occurrence of two distinct neoplasms, a lymphoma infiltrating the pleura and a primary, early lung adenocarcinoma.
  • Immunohistochemical and fluorescence in situ hybridization assays were performed.
  • The morphologic, immunophenotypic and genetic findings supported the diagnosis of primary lung adenocarcinoma (papillary subtype) coexisting with a non-Hodgkin, B-cell lineage, mantle cell lymphoma involving both, visceral and parietal pleura and without mediastinal lymph node involvement.
  • The patient received 6 cycles of chemotherapy, while pulmonary function tests precluded further pulmonary parenchyma resection (lobectomy) for his adenocarcinoma.
  • CONCLUSION: This is the first reported case of a rare tumoral combination involving simultaneously lung and pleura, emphasizing at the incidental discovery of the two coexisting neoplasms during a procedure performed for a benign condition.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Lymphoma, Mantle-Cell / pathology. Neoplasms, Multiple Primary / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2001 Jan;32(1):129-32 [11172307.001]
  • [Cites] Mod Pathol. 2001 Aug;14(8):811-7 [11504842.001]
  • [Cites] Thorac Cardiovasc Surg. 2002 Feb;50(1):59-61 [11847607.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):358-64 [11859208.001]
  • [Cites] Lancet Oncol. 2001 Mar;2(3):141-8 [11902564.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):101-9 [12502932.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):E64-6 [12562254.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):409-14 [15101734.001]
  • [Cites] Hum Pathol. 1984 Jul;15(7):625-31 [6378757.001]
  • [Cites] Histopathology. 1995 Jan;26(1):17-24 [7713480.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2715-23 [7670110.001]
  • [Cites] Postgrad Med J. 1995 Jul;71(837):443 [7567744.001]
  • [Cites] An Med Interna. 2006 Jun;23(6):301-2 [17078163.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1497-502 [17090191.001]
  • [Cites] Mod Pathol. 2007 Jun;20(6):638-47 [17431413.001]
  • (PMID = 19114021.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2629472
  •  go-up   go-down


3. Pankiewicz W, Minarowski L, Niklińska W, Naumnik W, Nikliński J, Chyczewski L: Immunohistochemical markers of cancerogenesis in the lung. Folia Histochem Cytobiol; 2007;45(2):65-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical markers of cancerogenesis in the lung.
  • Lung cancer is the leading cause of cancer deaths for people of both sexes worldwide.
  • Early diagnosis of precancer lesions may be of crucial significance to lowering lung cancer mortality.
  • The World Health Organization has defined three preneoplastic lesions of the bronchial epithelium: squamous dysplasia and carcinoma in situ, atypical adenomatous hyperplasia and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia.
  • These lesions are believed to progress to squamous cell carcinoma, adenocarcinoma and carcinoid tumors, respectively.
  • Apart from WHO classification, two other lesions such as bronchiolization and bronchiolar columnar cell dysplasia (BCCD) can be observed and thought to be preneoplastic lesions leading to adenocarcinoma.
  • In this review we summarize the data of morphological and cell cycle related proteins changes in both central and peripheral compartments of lung.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597018.001).
  • [ISSN] 0239-8508
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 67
  •  go-up   go-down


Advertisement
4. Yendamuri S, Vaporciyan AA, Zaidi T, Feng L, Fernandez R, Bekele NB, Hofstetter WL, Jiang F, Mehran RJ, Rice DC, Spitz MR, Swisher SG, Walsh GL, Roth JA, Katz RL: 3p22.1 and 10q22.3 deletions detected by fluorescence in situ hybridization (FISH): a potential new tool for early detection of non-small cell lung Cancer (NSCLC). J Thorac Oncol; 2008 Sep;3(9):979-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 3p22.1 and 10q22.3 deletions detected by fluorescence in situ hybridization (FISH): a potential new tool for early detection of non-small cell lung Cancer (NSCLC).
  • BACKGROUND: Our objective was to study the feasibility of detecting chromosomal deletions at 3p22.1 and 10q22.3 by fluorescent in situ hybridization (FISH) and to examine their distribution in different areas of the airway in patients with non-small cell lung cancer.
  • Touch preparations from the tumor (TTP), normal lung parenchyma, and bronchi adjacent to the tumor were also obtained.
  • A significantly higher deletion rate was seen at TTP compared with normal lung parenchyma at both the 3p22.1 and 10 q22.3 (p < 0.0001).
  • This suggests that, FISH analysis of bronchoscopic brushes may be useful for identifying patients at high risk for developing non-small cell lung cancer.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1981 Mar 1;47(5 Suppl):1114-20 [6263442.001]
  • [Cites] Cancer Detect Prev. 2004;28(4):244-51 [15350627.001]
  • [Cites] Biochim Biophys Acta. 1988 Jun 30;970(2):194-204 [3382698.001]
  • [Cites] Chest. 1998 Mar;113(3):696-702 [9515845.001]
  • [Cites] Carcinogenesis. 1999 Aug;20(8):1403-10 [10426784.001]
  • [Cites] Cancer Gene Ther. 2004 Nov;11(11):733-9 [15486560.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):623-35 [15548372.001]
  • [Cites] Cancer. 2005 Feb 25;105(1):35-43 [15605362.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5417-24 [16061856.001]
  • [Cites] Chest. 2006 Jun;129(6):1629-35 [16778285.001]
  • [Cites] Chest. 2006 Sep;130(3):694-701 [16963665.001]
  • [Cites] N Engl J Med. 2006 Oct 26;355(17):1763-71 [17065637.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Dec;132(6):1382-9 [17140961.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Aug;4(8):440-1 [17563776.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):950-60 [18500269.001]
  • [Cites] Diagn Mol Pathol. 2002 Mar;11(1):47-57 [11854602.001]
  • [Cites] Oncogene. 2002 Oct 7;21(45):6915-35 [12362274.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):232-6 [12432269.001]
  • [Cites] Lung Cancer. 2002 Dec;38 Suppl 3:S9-17 [12468138.001]
  • [Cites] J Mol Diagn. 2003 May;5(2):103-12 [12707375.001]
  • [Cites] Curr Opin Pulm Med. 2003 Jul;9(4):309-12 [12806245.001]
  • [Cites] Histopathology. 2004 Feb;44(2):147-55 [14764058.001]
  • [Cites] Hum Genet. 1987 May;76(1):58-62 [3032770.001]
  • (PMID = 18758299.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / R01 CA055769; United States / NCI NIH HHS / CA / CA 55769; United States / NCI NIH HHS / CA / P50CA70907
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS381558; NLM/ PMC3370669
  •  go-up   go-down


5. Shen H, Zhu Y, Wu YJ, Qiu HR, Shu YQ: Genomic alterations in lung adenocarcinomas detected by multicolor fluorescence in situ hybridization and comparative genomic hybridization. Cancer Genet Cytogenet; 2008 Mar;181(2):100-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic alterations in lung adenocarcinomas detected by multicolor fluorescence in situ hybridization and comparative genomic hybridization.
  • We used two molecular cytogenetic techniques, multicolor fluorescence in situ hybridization (M-FISH) and comparative genomic hybridization (CGH), to analyze three established lung adenocarcinoma cell lines (A549, H1650, and SPC-A-1) and primary lung adenocarcinoma samples, to identify common chromosomal aberrations.
  • The most common gains were found in 16p13 (in 50% of samples), and 16p13 amplification was associated with relatively poor differentiation and late stage.
  • M-FISH and CGH can be a powerful tool in identification of genomic alterations in lung cancer, as well as in diagnosis.
  • The overrepresented regions may harbor potential candidate genes involved in lung adenocarcinoma pathogenesis.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. In Situ Hybridization, Fluorescence / methods. Lung Neoplasms / genetics. Nucleic Acid Hybridization
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / genetics. Cell Line, Tumor. Color. Genome, Human. Humans. Karyotyping

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18295661.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Pajares MJ, Zudaire I, Lozano MD, Agorreta J, Bastarrika G, Torre W, Remírez A, Pio R, Zulueta JJ, Montuenga LM: Molecular profiling of computed tomography screen-detected lung nodules shows multiple malignant features. Cancer Epidemiol Biomarkers Prev; 2006 Feb;15(2):373-80
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular profiling of computed tomography screen-detected lung nodules shows multiple malignant features.
  • RATIONALE AND PURPOSE: Low-dose spiral computerized axial tomography (spiral CT) is effective for the detection of small early lung cancers.
  • The objective of the current study was to analyze the phenotypic and genetic alterations in the small pulmonary malignancies resected after detection in the University of Navarra/International Early Lung Cancer Action Project spiral CT screening trial and to determine whether their malignant molecular features are similar to those of resected lung tumors diagnosed conventionally.
  • EXPERIMENTAL DESIGN: We analyzed 17 biomarkers of lung epithelial malignancy in a series of 11 tumors resected at our institution during the last 4 years (1,004 high-risk individuals screened), using immunohistochemistry and fluorescence in situ hybridization (FISH).
  • A parallel series of 11 gender-, stage-, and histology-matched lung cancers diagnosed by other means except screening was used as control.
  • RESULTS: The molecular alterations and the frequency of phenotypic or genetic aberrations were very similar when screen-detected and nonscreen-detected lung cancers were compared.
  • Furthermore, most of the alterations found in the screen-detected cancers from this study were concordant with what has been described previously for stage I-II lung cancer.
  • CONCLUSIONS: Small early-stage lung cancers resected after detection in a spiral CT-based screening trial reveal malignant molecular features similar to those found in conventionally diagnosed lung cancers, suggesting that the screen-detected cancers are not overdiagnosed.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / genetics. Lung Neoplasms / genetics. Tomography, Spiral Computed
  • [MeSH-minor] Early Diagnosis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Mass Screening. Neoplasm Staging. Phenotype. Sensitivity and Specificity. Smoking

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16492931.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Noguchi M, Minami Y, Iijima T, Matsuno Y: Reproducibility of the diagnosis of small adenocarcinoma of the lung and usefulness of an educational program for the diagnostic criteria. Pathol Int; 2005 Jan;55(1):8-13
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproducibility of the diagnosis of small adenocarcinoma of the lung and usefulness of an educational program for the diagnostic criteria.
  • Using 32 small adenocarcinomas of the lung including bronchioloalveolar carcinoma (BAC), the reproducibility of diagnosis by the modified diagnostic criteria for small adenocarcinoma (Cancer 75; 2844, 1995) and the effectiveness of an educational program for 27 volunteer general pathologists were examined.
  • The average coincidence rate of the diagnosis before and after the program was 42.4% and 56.6%, respectively.
  • In contrast, the average coincidence rate of six lung cancer specialists was 71.4%, and this was significantly higher than that for general pathologists after the program (P < 0.05).
  • When the cases were divided into two groups (in situ adenocarcinoma (BAC and BAC with alveolar collapse) and early invasive adenocarcinoma), the average coincidence rate for the general pathologists after the program increased to 85.3%, which was significantly higher than that before the program (80.3%; P < 0.05).
  • This trial was thought to provide a theoretical background for the histological diagnosis of peripheral type adenocarcinoma of the lung and to justify the existing diagnostic criteria.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Lung Neoplasms / diagnosis. Pathology, Surgical / education
  • [MeSH-minor] Diagnosis, Differential. Humans. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660697.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


8. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA: Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res; 2005 May 15;11(10):3766-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm.
  • PURPOSE: Patients with metastatic adenocarcinoma of unknown origin are a common clinical problem.
  • In the first (training) round, we studied 352 primary adenocarcinomas, from seven main sites (breast, colon, lung, ovary, pancreas, prostate and stomach) and their differential diagnoses.
  • CONCLUSIONS: This classification scheme should enable better prediction on biopsy material of the primary site in patients with metastatic adenocarcinoma of unknown origin, leading to improved management and therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization. Predictive Value of Tests. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897574.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Li R, Wang H, Bekele BN, Yin Z, Caraway NP, Katz RL, Stass SA, Jiang F: Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach. Oncogene; 2006 Apr 27;25(18):2628-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach.
  • We used a functional genomic approach that integrated simultaneous genomic and transcript microarray, proteomics, and tissue microarray analyses to directly identify putative oncogenes in lung adenocarcinoma.
  • We first identified 183 genes with increases in both genomic copy number and transcript in six lung adenocarcinoma cell lines.
  • Parallel fluorescence in situ hybridization and immunohistochemical analyses of EEF1A2 and KCIP-1 in tissue microarrays from patients with lung adenocarcinoma showed that gene amplification was associated with high protein expression for both genes and that protein overexpression was related to tumor grade, disease stage, Ki-67 expression, and a shorter survival of patients.
  • The amplification of EEF1A2 and KCIP-1 and the presence of overexpressed protein in tumor samples strongly suggest that these genes could be oncogenes and hence potential targets for diagnosis and therapy in lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Neoplasm Proteins / genetics. Oncogenes / genetics
  • [MeSH-minor] Electrophoresis, Gel, Two-Dimensional. Gene Amplification. Gene Dosage. Gene Expression Profiling. Genomics. Humans. In Situ Hybridization, Fluorescence. Oligonucleotide Array Sequence Analysis. Peptide Elongation Factor 1 / antagonists & inhibitors. Peptide Elongation Factor 1 / genetics. Peptide Elongation Factor 1 / metabolism. RNA, Small Interfering / genetics. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Tissue Array Analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16369491.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA113707-01; United States / NCI NIH HHS / CA / P50 CA70907
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / EEF1A2 protein, human; 0 / Neoplasm Proteins; 0 / Peptide Elongation Factor 1; 0 / RNA, Small Interfering
  •  go-up   go-down


10. Ikeda S, Takabe K, Inagaki M, Funakoshi N, Suzuki K: [Detection of ALK positive pulmonary adenocarcinoma using immunostaining]. Rinsho Byori; 2010 Jun;58(6):565-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of ALK positive pulmonary adenocarcinoma using immunostaining].
  • Although ALK-positive lung cancer cases have been recently reported, it is impossible to detect using only morphology technique.
  • We investigated whether ALK-positive lung cancer could be detected using a conventional immunostaining method.
  • Resected lung adenocarcinoma samples from 88 nonsmoker cases were selected and screening was performed using ALK immunostaining in 24 cases that did not have the EGFR or k-ras mutation.
  • Detection by immunostaining was found useful for ALK mutated lung cancer cases, though the pretreatment and detection methods utilized are important.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Lung Neoplasms / diagnosis. Mutation. Oncogene Proteins, Fusion / analysis. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Chimerin Proteins / genetics. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20662267.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chimerin Proteins; 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


11. Collins BT, Janney CG, Ong M, Cortese C: Fine needle aspiration biopsy of monophasic spindle synovial sarcoma of lung with fluorescence in situ hybridization identification of t(x;18) translocation: a case report. Acta Cytol; 2009 Jan-Feb;53(1):105-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration biopsy of monophasic spindle synovial sarcoma of lung with fluorescence in situ hybridization identification of t(x;18) translocation: a case report.
  • The diagnosis can be challenging because of the ability to mimic other spindle cell neoplasms.
  • Within the lung, these neoplasms are rare and cytologic descriptions are limited.
  • CASE: A 58-year-old woman was diagnosed with colonic adenocarcinoma; chest computed tomography (CT) revealed a 5-cm solitary pulmonary mass, and CT-guided fine needle aspiration was performed.
  • A diagnosis of spindle cell neoplasm was rendered; it was believed to be a second neoplasm unrelated to the colonic adenocarcinoma.
  • On resection, the neoplasm demonstrated t(x:1 8) chromosomal translocation by fluorescence in situ hybridization.
  • CONCLUSION: In a spindled cell neoplasm arising as a single peripheral pulmonary nodule, monophacir spindle synorvial sarcoma should be considered in the differential diagnosis; detection of the t(x;18) chromosomal translocation can confirm the diagnosis.
  • [MeSH-major] Lung Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis. Sarcoma, Synovial / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Biopsy, Fine-Needle. Chromosomes, Human, Pair 18 / genetics. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / analysis. Translocation, Genetic. Vimentin / analysis

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248564.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Vimentin
  •  go-up   go-down


12. Antoine M: [Contribution of immunohistochemistry to the management of lung cancer: from morphology to diagnosis and treatment]. Rev Pneumol Clin; 2007 Jun;63(3):183-92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Contribution of immunohistochemistry to the management of lung cancer: from morphology to diagnosis and treatment].
  • [Transliterated title] Qu'apporte l'immunohistochimie à la prise en charge du cancer bronchique? De la morphologie au diagnostic et au traitement.
  • We detail here the contribution of IHC to the classification of lung cancer: small-cell lung cancer and other neuroendocrine tumors, basaloid carcinoma, large-cell carcinoma.
  • Using IHC techniques, pathologists can now determine with certainty that an intrathoracic adenocarcinoma is primary or secondary.
  • By demonstrating the presence of carcinomatous cells within the neighboring structures (pleura) or lymph nodes, IHC contributes to lung cancer staging, particularly when there are few of these elements morphologically difficult to distinguish.
  • IHC studies may also be requested in a forensic setting, for example to demonstrate that the lung cancer observed in a patient exposed to asbestosis is primary.
  • Other morphological techniques such as hybridization in situ or molecular biology techniques will further complete the histological diagnosis in the future.
  • [MeSH-major] Immunohistochemistry. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Chorionic Gonadotropin, beta Subunit, Human / analysis. Forecasting. Humans. Lymph Nodes / pathology. Lymphoma / pathology. Mediastinal Neoplasms / pathology. Melanoma / pathology. Neoplasm Staging. Neuroendocrine Tumors / pathology. Pleural Neoplasms / pathology. Prognosis. Sarcoma / pathology. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675942.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


13. Nicolas MM, Nayar R, Yeldandi A, De Frias DV: Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report. Acta Cytol; 2006 Nov-Dec;50(6):672-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report.
  • We report a case of metastatic postradiation EAS to the lungs that was mistaken for adenocarcinoma.
  • CASE: A 45-year-old woman who received radiotherapy for ductal carcinoma in situ (DCIS) 5 years previously had a local recurrence a year earlier and recent development of bilateral small pulmonary nodules.
  • Fine needle aspiration biopsy of the lung lesions showed round to oval tumor cells with amphophilic cytoplasm.
  • An interpretation of adenocarcinoma was rendered during assessment for specimen adequacy.
  • Review of the recurrent breast tumor (initially reported as DCIS) and a prior wedge resection of the lung nodules (reported as EAS) showed an epithelial-appearing tumor exhibiting an endothelial immunophenotype CONCLUSION: The cytologic features of EAS may resemble those of other neoplasms.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Hemangiosarcoma / secondary. Lung Neoplasms / secondary. Neoplasms, Radiation-Induced / pathology. Radiotherapy / adverse effects
  • [MeSH-minor] Biopsy, Fine-Needle / methods. Diagnosis, Differential. Epithelioid Cells / pathology. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152281.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Saad RS, Liu YL, Silverman JF: Distribution of basal/myoepithelial markers in benign and malignant bronchioloalveolar proliferations of the lung. Appl Immunohistochem Mol Morphol; 2010 May;18(3):219-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of basal/myoepithelial markers in benign and malignant bronchioloalveolar proliferations of the lung.
  • We investigated the staining pattern of commonly used basal cell/myoepithelial markers, such as p63 (a p53-homologous nuclear protein), basal cell-specific cytokeratin antibody (34betaE12, K903), and smooth muscle myosin heavy chain (SMMHC) in benign and malignant bronchioloalveolar proliferations of the lung.
  • We studied 85 lung lesions consisting of 35 bronchioloalveolar carcinoma, 30 well-differentiated adenocarcinoma, and 20 cases of benign lung lesions.
  • In normal lung, p63, K903, and SMMHC decorated the basal cells of large and small airways and occasional cells of terminal bronchioles.
  • For adenocarcinoma, a majority of the cases (28/30, 93%) were negative for p63 and K903; however, SMMHC showed artifactual staining in the desmoplastic stroma in 6/30 (20%) cases.
  • The staining pattern of basal cells in bronchioloalveolar carcinoma supports that these neoplasms may actually be carcinoma in-situ.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065853.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 3.6.1.- / Smooth Muscle Myosins
  •  go-up   go-down


15. Dacic S: EGFR assays in lung cancer. Adv Anat Pathol; 2008 Jul;15(4):241-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR assays in lung cancer.
  • The development of small-molecule inhibitors of the epidermal growth factor receptor (EGFR) resulted in new therapeutic options for patients with advanced lung cancer.
  • This observation revolutionized understanding of EGFR in lung carcinogenesis and resulted in numerous retrospective studies that correlated patient's response and molecular profile of the lung adenocarcinoma.
  • Multiple methodologic approaches were used including mutational analysis, fluorescence in situ hybridization, and immunohistochemistry.
  • [MeSH-major] Lung Neoplasms / genetics. Mutation / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / genetics. Humans. In Situ Hybridization, Fluorescence. Polymerase Chain Reaction. Prognosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580100.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 61
  •  go-up   go-down


16. Zudaire I, Lozano MD, Vazquez MF, Pajares MJ, Agorreta J, Pio R, Zulueta JJ, Yankelevitz DF, Henschke CI, Montuenga LM: Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates. Histol Histopathol; 2008 01;23(1):33-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates.
  • The computed tomography (CT)-based early lung cancer diagnostic technologies allow the detection of very small stage I lung tumors.
  • Fine Needle Aspiration (FNA) cytology is a well-recognised method for a rapid and accurate diagnosis of small lung tumors.
  • Molecular analysis of the FNA specimens could complement cytology diagnosis by the characterization of the biological traits at the preoperative stage.
  • In this study, we aimed to characterize the biological profile of 33 paraffin-embedded transthoracic FNA samples obtained from three groups of lung cancer patients: two groups of small early-detected lung adenocarcinomas (radiologically subsolid and solid nodules) and a third group of small metastatic adenocarcinomas.
  • Genetic analysis was performed by fluorescence in situ hybridization using the four-color LAVysion probe. p53 and Ki-67 protein expression was also evaluated by immunocytochemistry.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Fine-Needle / methods. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence / methods. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Staging. Paraffin Embedding / methods. Proto-Oncogene Proteins c-myc / metabolism. Receptor, Epidermal Growth Factor / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952855.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


17. Zhao R, Yang W, Wang Z, Li G, Qin W, Wang J: Treatment of transplanted tumor of lung adenocarcinoma A549 transfected by human somatostatin receptor subtype 2 (hsstr2) gene with 188Re-RC-160. Nucl Med Biol; 2010 Nov;37(8):977-87

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of transplanted tumor of lung adenocarcinoma A549 transfected by human somatostatin receptor subtype 2 (hsstr2) gene with 188Re-RC-160.
  • BACKGROUND AND AIM: Radionuclide-labeled somatostatin analogues selectively target somatostatin receptor (SSTR)-expressing tumors as a basis for diagnosis and treatment of these tumors.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Animals. Blotting, Western. Cell Line, Tumor. Cell Transformation, Neoplastic. Cloning, Molecular. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy. Male. Mice. Mice, Inbred BALB C. Tomography, Emission-Computed, Single-Photon. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21055629.001).
  • [ISSN] 1872-9614
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radioisotopes; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 2PK59M9GFF / vapreotide; 51110-01-1 / Somatostatin; 7440-15-5 / Rhenium; Adenocarcinoma of lung
  •  go-up   go-down


18. Levy MJ, Clain JE, Clayton A, Halling KC, Kipp BR, Rajan E, Roberts LR, Root RM, Sebo TJ, Topazian MD, Wang KK, Wiersema MJ, Gores GJ: Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA. Gastrointest Endosc; 2007 Sep;66(3):483-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA.
  • BACKGROUND: Studies indicate enhanced diagnostic accuracy for digital image analysis (DIA) and fluorescence in situ hybridization (FISH) versus routine cytology examination (RC) when biliary strictures are evaluated.
  • The final diagnosis was based on strict cytopathologic and imaging criteria and 12-month follow-up.
  • RESULTS: Malignancy was diagnosed in 30 of 42 patients, including esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, pancreatic mucinous cystic neoplasia, intraductal papillary mucinous neoplasia, metastatic forearm sarcoma, small cell and non-small cell lung cancer, thyroid carcinoma, malignant GI stromal tumor, melanoma, adenocarcinoma of unknown primary, and lymphoma.
  • [MeSH-major] Biopsy, Fine-Needle. Endosonography. Esophageal Neoplasms / pathology. Image Processing, Computer-Assisted. In Situ Hybridization, Fluorescence. Lymphatic Metastasis / pathology. Pancreatic Neoplasms / pathology. Stomach Neoplasms / pathology. Thyroid Neoplasms / pathology


19. Jiang F, Todd NW, Li R, Zhang H, Fang H, Stass SA: A panel of sputum-based genomic marker for early detection of lung cancer. Cancer Prev Res (Phila); 2010 Dec;3(12):1571-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A panel of sputum-based genomic marker for early detection of lung cancer.
  • Non-small cell lung cancer (NSCLC) is the leading cause of cancer death.
  • We previously identified genetic signatures whose genomic copy number aberrations were associated with early stage NSCLC.
  • We first optimized a panel of genes by using an in situ minichip for measuring changes of the signatures in sputum of a case-control cohort of 49 NSCLC patients, 49 patients with chronic obstructive pulmonary disease (COPD), and 49 healthy smokers.
  • The composite of the 6 genes produced 86.7% sensitivity and 93.9% specificity in distinguishing stage I NSCLC patients from the noncancer individuals.
  • Furthermore, the genes had higher sensitivity (86.9%) in identification of squamous cell carcinoma (SCC) than in adenocarcinoma of the lungs (80.8%; P < 0.05).
  • Validation of the genes in the independent cohort confirmed their diagnostic power that also showed higher accuracy for lung SCCs than for sputum cytology.
  • The gene panel could provide sputum-based markers that have the potential to improve early detection of lung SCCs.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Squamous Cell / diagnosis. Genetic Markers / genetics. Lung Neoplasms / diagnosis. Sputum / metabolism
  • [MeSH-minor] Aged. Case-Control Studies. Cohort Studies. Early Diagnosis. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Staging. ROC Curve. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 20864512.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA135382; United States / NCI NIH HHS / CA / R21 CA113707; United States / NCI NIH HHS / CA / CA-137742; United States / NCRR NIH HHS / RR / K12RR023250; United States / NCI NIH HHS / CA / CA-133956; United States / NCI NIH HHS / CA / R21 CA205746; United States / NCI NIH HHS / CA / R03 CA137742; United States / NCI NIH HHS / CA / R01 CA161837; United States / NCI NIH HHS / CA / CA-135382; United States / NCI NIH HHS / CA / R03 CA133956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


20. Dai X, Yang H: [Cloning of hnRNP A2/B1 gene and detection of its expression in lung cancer tissues]. Zhongguo Fei Ai Za Zhi; 2005 Aug 20;8(4):266-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cloning of hnRNP A2/B1 gene and detection of its expression in lung cancer tissues].
  • BACKGROUND: There is no any specific dynamic criterion in early diagnosis of lung cancer yet.
  • The aim of this study is to obtain the cDNA sequence of hnRNP A2/B1 and then determine its expression in patients with lung cancer, and to provide experimental data for the early diagnosis and treatment of lung cancer.
  • The fragment was cloned into PUCm-T plasmids and further sequenced. hnRNP A2/B1 expression was detected in 41 patients with lung cancer and 13 patients with carcinoma-free diseases by in situ hybridization.
  • The positive rate of hnRNP A2/B1 was 87.8% (36/41) in lung cancer tissues, which was significantly higher than that in control group (23.1%, 3/13) (P < 0.01).
  • Four subtypes of lung cancer all showed positive staining of hnRNP A2/B1 protein.
  • The positive rate of hnRNP A2/B1 was 91.3% (21/23) in squamous cell carcinoma, and 78.6% (11/14) in adenocarcinoma (P > 0.05).
  • It can highly express in lung cancer tissues, but it does not correlate with histological classification of lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21108879.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Savic S, Tapia C, Grilli B, Rufle A, Bihl MP, de Vito Barascud A, Herzog M, Terracciano L, Baty F, Bubendorf L: Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br J Cancer; 2008 Jan 15;98(1):154-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers.
  • Epidermal growth factor receptor (EGFR) gene mutations and increased copy numbers are considered as predictors of response to EGFR tyrosine kinase inhibitors (EGFR-TKI) in non-small-cell lung cancer (NSCLC).
  • Lung cancer diagnosis is often based on cytology alone.
  • Eighty-four cytological specimens from NSCLCs were prospectively analysed for EGFR gene mutation in exons 18-21 and EGFR gene copy numbers were evaluated by fluorescence in situ hybridisation (FISH).
  • Fluorescence in situ hybridisation results of cytological specimens were compared to the FISH results on matching biopsies (n=33).
  • Initial diagnosis of NSCLC was solely based on cytology in 37 out of 84 (44.0%) patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Mutation / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Biopsy. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / secondary. Exons / genetics. Feasibility Studies. Female. Gene Dosage. Humans. In Situ Hybridization, Fluorescence. Male. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neuroectodermal Tumors / genetics. Neuroectodermal Tumors / metabolism. Neuroectodermal Tumors / secondary. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):526-8; author reply 526-8 [16452569.001]
  • [Cites] Acta Cytol. 2005 Sep-Oct;49(5):471-6 [16334021.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Apr;58(1):31-45 [16531062.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):607-10 [16554736.001]
  • [Cites] J Eval Clin Pract. 2006 Apr;12(2):132-9 [16579821.001]
  • [Cites] Chest. 2006 Jun;129(6):1629-35 [16778285.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4409s-4415s [16857819.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6049-55 [17062680.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):387-98 [17011067.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7232-41 [17189394.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1239-47 [17192902.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):587-95 [17290067.001]
  • [Cites] Anal Quant Cytol Histol. 2001 Apr;23(2):93-100 [11332084.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1398-403 [12196365.001]
  • [Cites] Cell. 2002 Sep 20;110(6):669-72 [12297041.001]
  • [Cites] Eur Respir J. 2002 Oct;20(4):975-81 [12412692.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 14):3-9 [12422308.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):129S-136S [12527572.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5813-24 [14676101.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1103-9 [15020612.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41 [15292385.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3238-47 [15310767.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8919-23 [15604253.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):857-65 [15681531.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2106-10 [15788655.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2924-9 [15837743.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5900-9 [16043828.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6838-45 [15998906.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8081-92 [16204011.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • (PMID = 18087280.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2359717
  •  go-up   go-down


22. Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z: Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer; 2008 Mar 15;112(6):1325-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
  • The authors determined the frequency of aberrant promoter methylation of 15 genes in 28 resected primary nonsmall cell lung cancers (NSCLCs) and in 12 corresponding nonmalignant lung tissues.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. DNA Methylation. Genes, Tumor Suppressor. Lung Neoplasms / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Apoptosis Regulatory Proteins / genetics. Cadherins / genetics. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Case-Control Studies. CpG Islands. Cyclin-Dependent Kinase Inhibitor p15 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Death-Associated Protein Kinases. Female. Humans. In Situ Hybridization. Insulin-Like Growth Factor Binding Proteins / genetics. Lung / metabolism. Lung / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Tissue Inhibitor of Metalloproteinase-3 / genetics. Ubiquitin-Protein Ligases / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 18286531.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / CDH17 protein, human; 0 / Cadherins; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / H-cadherin; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / RNA, Messenger; 0 / TIMP3 protein, human; 0 / Tissue Inhibitor of Metalloproteinase-3; 0 / insulin-like growth factor binding protein-related protein 1; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 6.3.2.- / BRAP protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


23. Kettunen E, Salmenkivi K, Vuopala K, Toljamo T, Kuosma E, Norppa H, Knuutila S, Kaleva S, Huuskonen MS, Anttila S: Copy number gains on 5p15, 6p11-q11, 7p12, and 8q24 are rare in sputum cells of individuals at high risk of lung cancer. Lung Cancer; 2006 Nov;54(2):169-76
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Copy number gains on 5p15, 6p11-q11, 7p12, and 8q24 are rare in sputum cells of individuals at high risk of lung cancer.
  • Lung cancer specimens display recurrent copy number aberrations in distinguished chromosomal regions as compared with normal lung cells.
  • Such alterations have been utilized in design of fluorescence in situ hybridization (FISH) probe sets in attempts to improve the cytological diagnosis of lung cancer.
  • One of such probe sets, LAVysion, detects copy number changes in the centromeric region of chromosome 6 (CEP6), and regions 5p15, 8q24, and 7p12, often gained in lung cancer.
  • METHODS: We evaluated the feasibility of the LAVysion multi-color probe set in detection of individuals at high risk of lung cancer by applying the FISH probe set on smears prepared of induced sputa obtained from 20 lung cancer patients, 43 asbestos-exposed workers, 21 heavy tobacco smokers, and 15 healthy never-smokers.
  • RESULTS: The FISH probe set was slightly more sensitive than cytology alone in detecting lung cancer.
  • The proportions of individuals with copy number gains in sputa among the lung cancer patients, asbestos-exposed workers, tobacco smokers, and never-smokers were 50, 20, 12, and 27%, respectively, when three or more cells with a copy number gain detected by at least two different probes was used as the cut-off point.
  • In comparison, the sensitivity of cytology in detecting lung cancer was 44%.
  • In the lung cancer patients the number of abnormal cells by FISH correlated well with the cytologic atypia class (Spearman rank correlation coefficient 0.77, p<0.01).
  • CONCLUSIONS: FISH did not significantly exceed the sensitivity of sputum cytology in finding lung cancers.
  • More sensitive methods are needed for the follow-up of populations at high risk of contracting lung cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Lung Neoplasms / genetics. Sputum / cytology
  • [MeSH-minor] Adult. Aged. Asbestos / toxicity. Bronchi. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Risk. Sensitivity and Specificity. Smoking / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935392.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


24. Zeng X, Hood BL, Sun M, Conrads TP, Day RS, Weissfeld JL, Siegfried JM, Bigbee WL: Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. J Proteome Res; 2010 Dec 3;9(12):6440-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry.
  • Here we report its application to a set of pooled nonsmall cell lung cancer (NSCLC) case sera (9 adenocarcinoma and 6 squamous cell carcinoma pools from 54 patients) and matched controls pools, including 8 clinical control pools with computed tomography detected nodules but being nonmalignant as determined by biopsy from 54 patients, and 8 matched healthy control pools from 106 cancer-free subjects.
  • The goal of the study is to discover biomarkers that may enable improved early detection and diagnosis of lung cancer.
  • Hydrazide resin in situ trypsin digestion was used to release nonglycosylated peptides.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Gerontol. 2001 Sep;36(9):1551-63 [11525877.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):4-8 [10580125.001]
  • [Cites] Nat Biotechnol. 2003 Jun;21(6):660-6 [12754519.001]
  • [Cites] Nat Biotechnol. 2003 Jun;21(6):667-72 [12754521.001]
  • [Cites] Biomed Pharmacother. 2004 Jan;58(1):24-38 [14739059.001]
  • [Cites] Biotechnol Genet Eng Rev. 2003;20:199-244 [14997853.001]
  • [Cites] Curr Opin Chem Biol. 2004 Feb;8(1):66-75 [15036159.001]
  • [Cites] Jpn J Clin Oncol. 1986 Dec;16(4):335-46 [3467106.001]
  • [Cites] N Engl J Med. 1987 Oct 8;317(15):909-16 [2442609.001]
  • [Cites] Radiology. 1996 Dec;201(3):798-802 [8939234.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Jan;129(1):87-93 [15632829.001]
  • [Cites] Glycobiology. 2005 May;15(5):447-62 [15616123.001]
  • [Cites] Mol Cell Proteomics. 2005 Oct;4(10):1487-502 [15979981.001]
  • [Cites] J Proteome Res. 2005 Nov-Dec;4(6):2070-80 [16335952.001]
  • [Cites] Mol Cell Proteomics. 2006 Apr;5(4):573-88 [16332733.001]
  • [Cites] Proteomics. 2006 Jul;6(13):3938-48 [16767791.001]
  • [Cites] Mol Cell Proteomics. 2007 Jan;6(1):141-9 [17074749.001]
  • [Cites] Nat Protoc. 2007;2(2):334-9 [17406594.001]
  • [Cites] J Proteome Res. 2007 Sep;6(9):3475-83 [17705522.001]
  • [Cites] Arch Intern Med. 2007 Nov 26;167(21):2289-95 [18039986.001]
  • [Cites] Proteomics. 2007 Dec;7(23):4292-302 [17963278.001]
  • [Cites] J Proteomics. 2008 Apr 30;71(1):61-70 [18541474.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Nov 1;178(9):956-61 [18635890.001]
  • [Cites] Surg Oncol. 2009 Mar;18(1):15-24 [18619834.001]
  • [Cites] Electrophoresis. 2009 Apr;30(7):1206-20 [19294700.001]
  • [Cites] J Exp Clin Cancer Res. 2009;28:89 [19549343.001]
  • [Cites] Mol Cell Proteomics. 2009 Aug;8(8):1860-77 [19411661.001]
  • [Cites] Methods Mol Biol. 2010;604:273-83 [20013377.001]
  • [Cites] CA Cancer J Clin. 2010 Mar-Apr;60(2):99-119 [20228384.001]
  • [Cites] Cell. 2010 Mar 19;140(6):883-99 [20303878.001]
  • [Cites] Mol Cell Proteomics. 2002 Nov;1(11):845-67 [12488461.001]
  • (PMID = 20931982.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA090440; United States / NCI NIH HHS / CA / U01 CA084968-10; United States / NCI NIH HHS / CA / P50CA90440; United States / NCI NIH HHS / CA / U01 CA084968; United States / NCI NIH HHS / CA / P50 CA090440-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycopeptides; 0 / Glycoproteins
  • [Other-IDs] NLM/ NIHMS249067; NLM/ PMC3184639
  •  go-up   go-down


25. Zhu CQ, Cutz JC, Liu N, Lau D, Shepherd FA, Squire JA, Tsao MS: Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. Br J Cancer; 2006 May 22;94(10):1452-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer.
  • This study evaluates the prognostic value of hTERT gene amplification and mRNA overexpression in 144 resectable non-small-cell lung cancer (NSCLC) specimens.
  • The hTERT gene copy number was assessed by quantitative polymerase chain reaction (qPCR) on laser-capture microdissected tumour cells of 81 tumours, and by fluorescence in situ hybridisation (FISH) on a subset of 59 tumours. hTERT mRNA level was determined by reverse transcription (RT)-qPCR in 130 tumours.
  • In total, 57% of (46 out of 81) primary NSCLC specimens demonstrated hTERT amplification, which was significantly more common (P<0.001) in adenocarcinoma (30 out of 40) than in squamous cell carcinoma (13 out of 37).
  • The hTERT mRNA overexpression was noted in 74% (94 out of 130) of tumours; it was more frequent in squamous cell than in adenocarcinoma (87 vs 68%, P=0.03).
  • Overexpression was significantly associated with amplification (P=0.03), especially in adenocarcinoma.
  • These data indicate that gene amplification is an important mechanism for hTERT overexpression in lung adenocarcinoma and is an independent poor prognostic marker for disease-free survival in NSCLC.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Non-Small-Cell Lung / diagnosis. DNA-Binding Proteins / genetics. Gene Amplification. Lung Neoplasms / diagnosis. Telomerase / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Neoplasm / genetics. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2002 Jul;34(3):269-75 [12007187.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):541-52 [11850779.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3636-40 [12097266.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2883-9 [12231532.001]
  • [Cites] Cancer Cell. 2002 Oct;2(4):257-65 [12398889.001]
  • [Cites] Mutagenesis. 2002 Nov;17(6):539-50 [12435851.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):516-20 [12592364.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):1019-26 [12598334.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1763-9 [12759234.001]
  • [Cites] Lung Cancer. 2003 Aug;41(2):163-9 [12871779.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1008-13 [12942569.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3836-43 [14551302.001]
  • [Cites] Int J Oncol. 2004 Apr;24(4):925-30 [15010831.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1222-9 [15026805.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1984-91 [15041716.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2919-33 [15077154.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Aug;26(2):425-31 [15296909.001]
  • [Cites] Bioessays. 2004 Nov;26(11):1164-74 [15499579.001]
  • [Cites] Science. 1997 Aug 15;277(5328):955-9 [9252327.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1609-15 [9362159.001]
  • [Cites] Curr Biol. 1998 Feb 26;8(5):279-82 [9501072.001]
  • [Cites] Nat Genet. 1998 Jun;19(2):182-6 [9620778.001]
  • [Cites] Lung Cancer. 1998 Apr;20(1):1-16 [9699182.001]
  • [Cites] J Biol Chem. 1999 May 7;274(19):13085-90 [10224060.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):1050-5 [10491533.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4575-83 [15542809.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Nat Clin Pract Oncol. 2004 Dec;1(2):88-96 [16264826.001]
  • [Cites] Ann Surg. 1999 Nov;230(5):715-20 [10561097.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):452-9 [10690523.001]
  • [Cites] Int J Oncol. 2000 Jun;16(6):1173-7 [10811992.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):2181-7 [10928174.001]
  • [Cites] Ann Thorac Surg. 2000 Aug;70(2):401-5; discussion 405-6 [10969652.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6230-5 [11103775.001]
  • [Cites] Hum Pathol. 2001 Feb;32(2):188-95 [11230706.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Mar;125(2):87-99 [11369051.001]
  • [Cites] Int J Oncol. 2001 Nov;19(5):1063-8 [11605010.001]
  • [Cites] Lung Cancer. 2001 Nov;34(2):219-26 [11679180.001]
  • [Cites] Nucleic Acids Res. 2001 Dec 1;29(23):4818-25 [11726691.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2648-57 [11745200.001]
  • [Cites] Cancer Lett. 2002 Feb 8;176(1):81-91 [11790457.001]
  • [Cites] Lab Invest. 2002 Jun;82(6):729-36 [12065683.001]
  • (PMID = 16641908.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC2361293
  •  go-up   go-down


26. Lin JD, Chao TC: Follicular thyroid carcinoma: From diagnosis to treatment. Endocr J; 2006 Aug;53(4):441-8
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular thyroid carcinoma: From diagnosis to treatment.
  • Unusual presentations with bone, lung or soft tissue metastases in initial diagnosis of follicular thyroid carcinoma have been reported occasionally.
  • This implies how difficult it is to diagnosis this type of cancer at the pre-operative or intra-operative stage of treatment.
  • Clinical application of various gene expressions in thyroid follicular tumors by needle aspiration using in situ hybridization requires further investigation.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / therapy. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / therapy
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Diagnostic Imaging. Humans. Iodine Radioisotopes / therapeutic use. Predictive Value of Tests. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807500.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Iodine Radioisotopes
  • [Number-of-references] 72
  •  go-up   go-down


27. Chung JH, Choe G, Jheon S, Sung SW, Kim TJ, Lee KW, Lee JH, Lee CT: Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol; 2009 Dec;4(12):1490-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread.
  • INTRODUCTION: No standard guidelines detailing recommendations for the selection and treatment for multiple lung nodules with ground-glass opacity (GGO) have been established.
  • For treatment decision, we analyzed epidermal growth factor receptor (EGFR)/K-ras somatic aberrations and pathologic-radiologic correlation in multiple lung nodules presented as GGO to differentiate multifocal lesions from intrapulmonary spread.
  • METHODS: Twenty-four patients with multiple lung nodules presented as GGO were identified to investigate somatic mutations of EGFR (exon 18-21) and K-ras (codons 2, 13, and 61).
  • RESULTS: High frequency of discordant EGFR mutations (17 of 24, 70.8%) could discriminate tumor clonality (18 of 24, 75%) of multiple lung neoplastic nodules presented as GGO.
  • These findings might be a clue to establish guidelines of the multiple neoplastic lung nodules with GGO.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Carcinoma in Situ / pathology. Hyperplasia / pathology. Lung Neoplasms / pathology. Mutation / genetics. Precancerous Conditions / pathology. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Genotype. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. Proto-Oncogene Proteins / blood. Proto-Oncogene Proteins / genetics. Tomography, X-Ray Computed. ras Proteins / blood. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19844187.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


28. Kerr KM: Pulmonary adenocarcinomas: classification and reporting. Histopathology; 2009 Jan;54(1):12-27
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary adenocarcinoma is the most common, and the most diverse form of primary lung carcinoma.
  • The current WHO classification of pulmonary adenocarcinoma does not adequately address a number of clinically relevant, biological factors.
  • The accurate diagnosis of adenocarcinoma on small biopsy specimens, accounting for most diagnoses of this disease, is challenged by the absence of tumour architecture in most samples.
  • Tumours showing a pure bronchioloalveolar (BAC) pattern are now best regarded as adenocarcinoma-in-situ; yet invasive adenocarcinomas may also show elements with the BAC pattern, dictating a better prognosis but biologically not necessarily in-situ disease.
  • Multifocal BAC-pattern adenocarcinoma still poses considerable conceptual and diagnostic problems.
  • In early tumours of predominantly BAC (in-situ) pattern, the identification of invasion is particularly difficult, yet minor degrees of infiltration seem not to degrade prognosis.
  • It may therefore be possible to define a minimally invasive category of adenocarcinoma.
  • The rapid emergence of chemotherapeutic agents with histology-specific efficacy will increase the need for more accurate and specific diagnosis of adenocarcinoma on small samples.
  • Immunohistochemistry may help suggest this diagnosis when the features are non-specific but immunohistochemical findings are not diagnostic of this form of lung cancer.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187177.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Osoegawa A, Nosaki K, Miyamoto H, Kometani T, Hirai F, Ondo K, Seto T, Sugio K, Choi YL, Soda M, Mano H, Ichinose Y: Incidentally proven pulmonary "ALKoma". Intern Med; 2010;49(6):603-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genetic alterations of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) inversion were recently found in lung cancer.
  • Biopsy from her supraclavicular lymph nodes was performed to differentiate the diagnosis between lymphoma and lung cancer.
  • Pathologically, the lymph nodes had a feature of adenocarcinoma.
  • On the other hand, the commercially available chromosomal fluorescent in situ hybridization (FISH) analysis showed split signals of ALK, which was confirmed to be the EML4-ALK inversion.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Cell Cycle Proteins / genetics. Chromosome Inversion / genetics. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. Microtubule-Associated Proteins / genetics. Protein-Tyrosine Kinases / genetics. Serine Endopeptidases / genetics
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Lymph Nodes / pathology. Lymphoma / diagnosis. Lymphoma / pathology. Receptor Protein-Tyrosine Kinases

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20228600.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Microtubule-Associated Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 3.4.21.- / EML4 protein, human; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


30. Hosaka N, Kameko M, Nishimura H, Hosaka S: Prevalence of tuberculosis in small pulmonary nodules obtained by video-assisted thoracoscopic surgery. Respir Med; 2006 Feb;100(2):238-43
Genetic Alliance. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prevalence of tuberculosis in small solitary lesions of the lung obtained by video-assisted thoracoscopic surgery (VATS) is still unclear.
  • Of 103 lung lesions resected by VATS in 98 patients (47 men, 51 women), 19 were identified macroscopically as inflammatory changes, 78 were neoplastic, and 6 were undefined.
  • Presumptive diagnosis based on microscopic analysis of fresh specimen smears treated with Papanicolaou stain was performed in 19 lesions.
  • Isolation and identification of tuberculosis were based on microscopic findings of fresh material smears and sections of fixed specimens stained with Ziehl-Neelsen's dye, cultivation using egg-based Ogawa medium, and in situ hybridization between polymerase chain reaction (PCR) products of each of the 11 lesions and specific DNA sequences for Mycobacterium tuberculosis, M. avium, and M. intracellulare.
  • Of the 78 malignant lesions, final pathologies were primary lung cancer (n=59, 70.2%) and pulmonary metastatic cancer (n=19, 22.6%).
  • The most frequent primary malignant cancer was adenocarcinoma, which was found in 19 men and 28 women in the present study.
  • The results of the present study suggested that even though the prevalence of lung tuberculosis is low, attention should be paid to the presence of M. tuberculosis in specimens obtained by VATS.
  • [MeSH-major] Solitary Pulmonary Nodule / microbiology. Tuberculosis, Pulmonary / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Granuloma, Respiratory Tract / diagnosis. Humans. Lung Neoplasms / diagnosis. Male. Middle Aged. Thoracic Surgery, Video-Assisted

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Respir Med. 2006 Sep;100(9):1666; author reply 1667 [16831540.001]
  • (PMID = 15964180.001).
  • [ISSN] 0954-6111
  • [Journal-full-title] Respiratory medicine
  • [ISO-abbreviation] Respir Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Zlobec I, Raineri I, Schneider S, Schoenegg R, Grilli B, Herzog M, Savic S, Bubendorf L: Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens. Lung Cancer; 2010 May;68(2):192-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of this study were first, to systematically assess the inter-observer reproducibility of mean Epidermal Growth Factor Receptor (EGFR) gene copy number (MCN) in histological and cytological specimens from lung and non-lung cancers, second to compare the performance of this quantitative approach to the current Colorado criteria for the assessment of fluorescence in situ hybridization (FISH) positivity and third to develop a model to convert cytology into histology MCN.
  • The MCN is a reproducible scoring method for evaluating EGFR FISH in samples from lung and non-lung cancers.
  • [MeSH-major] Adenocarcinoma / diagnosis. Gene Dosage. In Situ Hybridization, Fluorescence. Lung Neoplasms / diagnosis. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Feasibility Studies. Humans. Observer Variation. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19616866.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


32. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H: Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res; 2008 Oct 15;14(20):6618-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: EML4-ALK is a fusion-type protein tyrosine kinase that is generated by inv(2)(p21p23) in the genome of non-small cell lung cancer (NSCLC).
  • EXPERIMENTAL DESIGN: Primers were designed to detect all possible in-frame fusions of EML4 to exon 20 of ALK, and a single-tube multiplex RT-PCR assay was done with total RNA from 656 solid tumors of the lung (n = 364) and 10 other organs.
  • RESULTS: From consecutive lung adenocarcinoma cases (n = 253), we identified 11 specimens (4.35%) positive for fusion transcripts, 9 of which were positive for the previously identified variants 1, 2, and 3.
  • No fusion transcripts were detected for other types of lung cancer (n = 111) or for tumors from 10 other organs (n = 292).
  • Genomic rearrangements responsible for the fusion events in NSCLC cells were confirmed by genomic PCR analysis and fluorescence in situ hybridization.
  • CONCLUSIONS: These data reinforce the importance of accurate diagnosis of EML4-ALK-positive tumors for the optimization of treatment strategies.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Exons / genetics. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / genetics. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / genetics. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / genetics. Cell Transformation, Neoplastic. Chromosome Inversion. DNA Primers / chemistry. Gene Rearrangement. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18927303.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / RNA, Neoplasm
  •  go-up   go-down


33. Tirabosco R, Lang-Lazdunski L, Diss TC, Amary MF, Rodriguez-Justo M, Landau D, Lorenzi W, Flanagan AM: Clear cell sarcoma of the mediastinum. Ann Diagn Pathol; 2009 Jun;13(3):197-200
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At thoracotomy, the mass was found tightly adherent to the esophageal wall and right lower lobe of the lung.
  • The diagnosis of clear cell sarcoma was supported by demonstrating the presence of an EWS gene rearrangement by fluorescence in situ hybridization.
  • We present the case and discuss the differential diagnosis.
  • [MeSH-minor] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Diagnosis, Differential. Female. Gastrointestinal Stromal Tumors / pathology. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lymphatic Metastasis / pathology. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433300.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA-Binding Protein EWS
  •  go-up   go-down


34. Achcar Rde O, Nikiforova MN, Dacic S, Nicholson AG, Yousem SA: Mammalian mastermind like 2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma. Hum Pathol; 2009 Jun;40(6):854-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the importance of the mammalian mastermind like 2 gene rearrangement and mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 fusion gene in bronchopulmonary mucoepidermoid carcinoma tumorigenesis and its differential diagnosis with primary pulmonary non-small-cell carcinomas, we evaluated the presence of the mammalian mastermind like 2 gene rearrangement and the mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 fusion in formalin-fixed, paraffin-embedded tissue sections from 17 adult bronchopulmonary mucoepidermoid carcinoma, 16 adenosquamous carcinomas, 24 squamous cell carcinomas, and 41 primary adenocarcinomas by fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction.
  • We detected mammalian mastermind like 2 gene rearrangement by fluorescence in situ hybridization analysis in 13 (77%) of 17 bronchopulmonary mucoepidermoid carcinoma cases (10 of 10 being low grade and 3 of 7 being high grade).
  • Reverse transcriptase polymerase chain reaction analysis confirmed positive fluorescence in situ hybridization results in 6 (43%) of 14 mucoepidermoid carcinoma cases.
  • None of the squamous, adenosquamous, or adenocarcinoma cases revealed the mammalian mastermind like 2 gene rearrangement by fluorescence in situ hybridization, and the mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 fusion product by reverse transcriptase polymerase chain reaction was not identified specifically in our adenosquamous carcinoma cases.
  • In conclusion, our study demonstrates that mammalian mastermind like 2 gene rearrangement and mucoepidermoid carcinoma translocated 1-mammalian mastermind like 2 fusion product can be detected by fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction analysis performed on low- and high-grade primary bronchopulmonary mucoepidermoid carcinoma and can be used to help discriminate low- and high-grade mucoepidermoid carcinoma from adenocarcinoma, adenosquamous carcinoma, and squamous cell carcinoma mimics in histologically challenging cases.
  • [MeSH-major] Bronchial Neoplasms / genetics. Carcinoma, Mucoepidermoid / genetics. DNA-Binding Proteins / genetics. Lung Neoplasms / genetics. Nuclear Proteins / genetics. Oncogene Proteins, Fusion / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adenosarcoma / genetics. Adenosarcoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Female. Gene Fusion. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Translocation, Genetic

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269006.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRTC1 protein, human; 0 / DNA-Binding Proteins; 0 / MAML2 protein, human; 0 / MECT1-MAML2 fusion protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors
  •  go-up   go-down


35. Manxhuka-Kerliu S, Telaku S, Ahmetaj H, Baruti A, Loxha S, Kerliu A: Colorectal cancer: prognostic values. Bosn J Basic Med Sci; 2009 Feb;9(1):19-24
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After lung cancer colorectal cancer (Cc) is ranked the second, as a cause of cancer-related death.
  • Adenocarcinoma was the most frequent histological type found in 85,90% of cases, in 60,94% of males and 39,06% of females; squamous cell carcinoma in 7,38%, in 63,63% of males and 36,36% of females; mucinous carcinoma in 4,68%, in 57,15% of males and 42,85% of females; while adenosquamous carcinoma, undifferentiated carcinoma and carcinoma in situ in 0,71% of cases each.
  • Dukes' stage and degree of differentiation provide independent prognostic information in Cc.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19284390.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


36. Gabrecht T, Glanzmann T, Freitag L, Weber BC, van den Bergh H, Wagnières G: Optimized autofluorescence bronchoscopy using additional backscattered red light. J Biomed Opt; 2007 Nov-Dec;12(6):064016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have performed a clinical study involving 41 lung cancers using modified autofluorescence bronchoscopy systems.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Bronchoscopy / methods
  • [MeSH-minor] Adenocarcinoma / diagnosis. Bronchi / pathology. Bronchoscopes. Carcinoma in Situ / diagnosis. Carcinoma, Small Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Fluorescence. Humans. Image Processing, Computer-Assisted. Light. Lung Neoplasms / diagnosis. Metaplasia / diagnosis. Predictive Value of Tests. Scattering, Radiation. Spectrometry, Fluorescence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18163832.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Noda K, Nakayama H, Kameda Y, Tsuchiya E, Miyagi Y: Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol; 2007 Jul;128(1):100-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.
  • Although adenocarcinomas of the lung are associated with epidermal growth factor receptor (EGFR) gene mutations and sensitivity to EGFR tyrosine kinase inhibitors, it remains unclear whether bronchioloalveolar carcinoma (BAC) components and/or subtypes affect these associations.
  • We examined 141 non-small cell lung cancers (NSCLCs), including 118 adenocarcinomas, for mutations in exons 19 and 21 of the EGFR gene together with mutations in codon 12 of the K-ras gene using loop-hybrid mobility shift assays, a highly sensitive polymerase chain reaction-based method.
  • In NSCLCs, EGFR mutations were detected in 75 cases (53.2%) and were significantly associated with adenocarcinoma, female sex, and never smoking.
  • Because EGFR mutations were detected even in most pure nonmucinous BACs, ie, lung adenocarcinoma in situ, EGFR mutation is considered a critical event in the pathogenesis of nonmucinous BAC tumors.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Genes, ras. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. Carcinoma, Non-Small-Cell Lung / genetics. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580276.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


38. Reid-Nicholson M, Kavuri S, Ustun C, Crawford J, Nayak-Kapoor A, Ramalingam P: Plasmablastic lymphoma: Cytologic findings in 5 cases with unusual presentation. Cancer; 2008 Oct 25;114(5):333-41
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients had the acquired immunodeficiency syndrome and 3 had second non-PBL related malignancies including endometrial carcinoma, lung adenocarcinoma, and small lymphocytic lymphoma.
  • However, although these findings may suggest PBL, a definitive diagnosis requires adjunctive studies including immunohistochemistry and flow cytometry.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Adult. Female. HIV Infections / complications. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18683216.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Ludwick C, Gilks CB, Miller D, Yaziji H, Clement PB: Aggressive behavior of stage I ovarian mucinous tumors lacking extensive infiltrative invasion: a report of four cases and review of the literature. Int J Gynecol Pathol; 2005 Jul;24(3):205-17
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive behavior of stage I ovarian mucinous tumors lacking extensive infiltrative invasion: a report of four cases and review of the literature.
  • We present four cases of stage I ovarian mucinous tumors that lacked extensive infiltrative invasion but were associated with an unexpectedly aggressive behavior.
  • The tumors were all stage Ia, 17 to 37 centimeters in maximal dimension, and typically multicystic with solid areas.
  • On follow-up, each patient experienced recurrent disease 7 months to 4.5 years after diagnosis, including hematogenous spread to lung and/or bone and liver in three patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma in Situ / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968194.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


40. Puebla-Mora AG, Heras A, Cano-Valdez AM, Domínguez-Malagón H: Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study. Ann Diagn Pathol; 2006 Aug;10(4):205-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human telomerase detected by in situ hybridization has been demonstrated to be a useful tool for the diagnosis of malignancy and has also been tested by reverse transcriptase-polymerase chain reaction in several tumors such as hepatic cell carcinoma, melanoma, colonic carcinoma, gastric carcinoma, biliary carcinoma, breast carcinoma, mesothelioma, lung carcinoma, female tract carcinoma, and prostatic carcinoma.
  • [MeSH-major] Adenocarcinoma / enzymology. DNA-Binding Proteins / metabolism. Immunoenzyme Techniques / methods. Prostatic Intraepithelial Neoplasia / enzymology. Prostatic Neoplasms / enzymology. Racemases and Epimerases / metabolism. Telomerase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844561.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 2.7.7.49 / Telomerase; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


41. Barnett BP, Sheth S, Ali SZ: Cytopathologic analysis of paratracheal masses: a study of 737 cases with clinicoradiologic correlation. Acta Cytol; 2009 Nov-Dec;53(6):672-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the malignant cases, 45 (73%) were metastatic tumors: adenocarcinoma (ACA) 19, small cell carcinoma 12, squamous cell carcinoma (SQCC) 11 and other tumors, from lung 34, esophagus 4 and other sites.
  • Malignant neoplasms from local spread included lung non-small cell carcinoma 6, SQCC 3 and ACA 3, papillary thyroid carcinoma 3 and other 2.
  • The most common diagnosis is a malignant tumor (60%), with metastatic carcinoma (73%) the most common neoplasm (lung ACA the most common primary source).
  • Ancillary studies (immunoctyochemistry, fluorescence in situ hybridization and electron microscopy) were helpful and provided definitive diagnosis in 30% of the initially nondiagnostic FNA samples.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20014557.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


42. Bono F: Pleural mesothelioma in situ and its adenocarcinoma simulator. Int J Surg Pathol; 2010 Dec;18(6):519-20
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleural mesothelioma in situ and its adenocarcinoma simulator.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Lung Neoplasms / pathology. Mesothelioma / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21081535.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


43. Goyal A, Chen S: Bronchioloalveolar carcinoma is really carcinoma in situ. Arch Pathol Lab Med; 2008 Oct;132(10):1548
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchioloalveolar carcinoma is really carcinoma in situ.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Carcinoma in Situ / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Arch Pathol Lab Med. 2007 Jul;131(7):1027-32 [17616987.001]
  • (PMID = 18834206.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


44. Dacic S, Yousem SA: Molecular testing in lung carcinoma: Quo vadis? Am J Clin Pathol; 2010 Jul;134(1):7-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular testing in lung carcinoma: Quo vadis?
  • [MeSH-major] Adenocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Molecular Diagnostic Techniques
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. DNA Mutational Analysis. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization, Fluorescence. Point Mutation. Prognosis. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Clin Pathol. 2010 Jun;133(6):922-34 [20472851.001]
  • (PMID = 20551260.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down






Advertisement